Optimized rapamycin-loaded PEGylated PLGA nanoparticles: Preparation, characterization and pharmacokinetics study

被引:12
作者
Cheraga, Nihad [1 ]
Sun, Ning-Cong [1 ]
Huang, Xiao-Xiao [1 ]
Ye, Zheng [1 ]
Xiao, Qian-Ru [1 ]
Huang, Ning-Ping [1 ]
机构
[1] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Peoples R China
基金
中国国家自然科学基金;
关键词
Rapamycin; PEGylated nanoparticles; PLGA; Particle size; Orthogonal design; IN-VIVO EVALUATION; PEG NANOPARTICLES; CONTROLLED-RELEASE; TAGUCHI METHOD; DRUG-RELEASE; DELIVERY; VITRO; BIODISTRIBUTION; PARAMETERS; SIROLIMUS;
D O I
10.1016/j.jddst.2020.102144
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rapamycin (RAP), an inhibitor of mTOR signaling pathway, has been widely used for its immunosuppressive activity over its anti-tumor and anti-inflammatory properties. The objective of this study was to encapsulate RAP into appropriately sized PEGylated nanoparticles, using biodegradable polyethylene glycol-poly (D, L-lactide-co-glycolide) copolymer (PEG-PLGA), for preferential tumor delivery through the enhanced permeability and retention (EPR) effect. Taguchi experimental design was used to determine the optimum preparation conditions for desirable sized nanoparticles and particle size was set as characteristic response. Nanoprecipitation method was used to prepare nanoparticles and the effects of stirring time, Tween 80 concentration, and RAP/PEG-PLGA ratio on nanoparticles size were investigated. The particle size of RAP-loaded PEGylated PLGA nanoparticles (RPP NPs) prepared using optimum conditions was about 118.8 nm. The release of RAP from optimized RPP NPs followed a non-Fickian sustained release pattern over a period of 7 days. In addition, the in vitro cytotoxicity of RPP NPs was investigated on various cell lines, and human leukemic Jurkat T cells revealed the lowest IC50 value. RPP NPs showed a good stability when stored for one month at 4 degrees C. The in vivo study on mice model showed enhanced pharmacokinetic profile of loaded RAP compared to its free form. Therefore, RPP NPs could be a potential therapeutic system for cancer and inflammatory disorder therapies.
引用
收藏
页数:11
相关论文
共 80 条
  • [1] Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
    Acharya, Sarbari
    Dilnawaz, Fahima
    Sahoo, Sanjeeb K.
    [J]. BIOMATERIALS, 2009, 30 (29) : 5737 - 5750
  • [2] Preparation of Drug-Loaded PLGA-PEG Nanoparticles by Membrane-Assisted Nanoprecipitation
    Albisa, Airama
    Piacentini, Emma
    Sebastian, Victor
    Arruebo, Manuel
    Santamaria, Jesus
    Giorno, Lidietta
    [J]. PHARMACEUTICAL RESEARCH, 2017, 34 (06) : 1296 - 1308
  • [3] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [4] [Anonymous], FDDSF, P163
  • [5] [Anonymous], 1997, IIE TRANS
  • [6] [Anonymous], [No title captured]
  • [7] [Anonymous], 2017, PHARM, V524, P257
  • [8] Multi response optimisation of CNC turning parameters via Taguchi method-based response surface analysis
    Asilturk, Ilhan
    Neseli, Suleyman
    [J]. MEASUREMENT, 2012, 45 (04) : 785 - 794
  • [9] PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties
    Avgoustakis, K
    Beletsi, A
    Panagi, Z
    Klepetsanis, P
    Karydas, AG
    Ithakissios, DS
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) : 123 - 135
  • [10] Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals
    Bagalkot, Vaishali
    Badgeley, Marcus A.
    Kampfrath, Thomas
    Deiuliis, Jeffrey A.
    Rajagopalan, Sanjay
    Maiseyeu, Andrei
    [J]. JOURNAL OF CONTROLLED RELEASE, 2015, 217 : 243 - 255